PCM
DFTX

Penserra Capital Management’s Definium Therapeutics DFTX Stock Holding History

Penserra Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-29,458
Closed -$282K – 1116
2022
Q2 		$282K Sell
29,458
-2,599
-8% -$32.9K 0.01% 590
2022
Q1 		$442K Buy
32,057
+15,916
+99% +$276K 0.01% 519
2021
Q4 		$334K Buy
16,141
+3,073
+24% +$98.1K 0.01% 577
2021
Q3 		$456K Buy
13,068
+4,841
+59% +$209K 0.01% 522
2021
Q2 		$425K Buy
+8,227
New +$432K 0.01% 534

Other funds holding DFTX

DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Penserra Capital Management's DFTX Position: Q3 2022 in Review

Penserra Capital Management sold out of Definium Therapeutics (DFTX) in Q3 2022, closing a stake of 29,458 shares — an estimated $282K sold.

Penserra Capital Management first reported a position in DFTX in Q2 2021 and held it in 5 quarters. The position peaked at $456K in Q3 2021. 101 funds tracked by Wall St. Rank hold DFTX as of Q3 2022.

  • Penserra Capital Management reported no remaining Definium Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 29,458 Definium Therapeutics shares in Q3 2022, an estimated $282K.
  • Penserra Capital Management first reported a position in Definium Therapeutics in Q2 2021 and held it in 5 quarters.
  • Penserra Capital Management's Definium Therapeutics position peaked at $456K in Q3 2021.
  • 101 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.